Hepion director gets 299K stock options at $0.08

Hepion Pharmaceuticals, Inc. (HEPA) reported that director James Gordon Liddy received a grant of stock options.

Rhea-AI Filing Summary

Hepion Pharmaceuticals, Inc. (HEPA) reported that director James Gordon Liddy received a grant of stock options. The award covers 299,000 stock options, each for one share of common stock, with an exercise price of $0.08 per share, exercisable from August 19, 2027 until August 19, 2036. Following this grant, he holds 299,000 stock options directly.

Insider Trade Summary

Grant/Award: 299,000 shares

Grant/Award 1 txn

Insider Liddy James Gordon

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	299,000	$0.00	$0.00

Holdings After Transaction: Stock Options — 299,000 contracts (Direct)

Key Figures

Stock options granted: 299,000 options Exercise price: $0.08 per share Underlying common stock: 299,000 shares +3 more

6 metrics

Stock options granted 299,000 options Grant of stock options to director James Gordon Liddy

Exercise price $0.08 per share Exercise price of the granted stock options

Underlying common stock 299,000 shares Shares of common stock underlying the options

Exercise date August 19, 2027 Date from which the options are exercisable

Expiration date August 19, 2036 Expiration of the granted stock options

Options held after transaction 299,000 options Total stock options directly held by James Gordon Liddy after the grant

Key Terms

Stock Options, exercise price, expiration date

3 terms

Stock Options financial

"The award covers 299,000 <b>stock options</b>, each for one share"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"with an <b>exercise price</b> of $0.08 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"and an <b>expiration date</b> of August 19, 2036"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did HEPA disclose for James Gordon Liddy?

HEPA disclosed that director James Gordon Liddy received a grant of 299,000 stock options for common stock at an exercise price of $0.08 per share, exercisable from August 19, 2027 to August 19, 2036. After the grant, he directly holds 299,000 options.

Was the HEPA Form 4 transaction a buy or a sell?

The Form 4 for HEPA reports an acquisition of derivative securities. James Gordon Liddy received a grant of 299,000 stock options; there were no reported sales of common stock or options in this filing.

What is the exercise price of the options granted in the HEPA Form 4?

The stock options granted to James Gordon Liddy have an exercise price of $0.08 per share for the underlying HEPA common stock, as reported in the Form 4 transaction details.

When do the HEPA options granted to James Gordon Liddy become exercisable and when do they expire?

The reported stock options associated with HEPA become exercisable on August 19, 2027 and have an expiration date of August 19, 2036, providing a multi-year window in which they may be exercised.

How many HEPA stock options does James Gordon Liddy hold after this transaction?

After this grant, James Gordon Liddy is reported to hold 299,000 stock options directly, each representing the right to acquire one share of HEPA common stock, according to the Form 4 data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/21/2026 - 04:30 PM EDT Accepted by SEC EDGAR 08/21/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Liddy James Gordon

(Last) (First) (Middle)

C/O HEPION PHARMACEUTICALS, INC.

34 SHREWSBURY AVE., SUITE 1D

(Street)

RED BANK, NEW JERSEY 07701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Hepion Pharmaceuticals, Inc. [ HEPA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$0.08	08/19/2026		A		299,000		08/19/2027	08/19/2036	Common Stock	299,000	$0	299,000	D

Explanation of Responses:

	/s/ James G. Liddy	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)